Barclays Cuts Thermo Fisher Scientific (NYSE:TMO) Price Target to $450.00

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) had its price target reduced by stock analysts at Barclays from $475.00 to $450.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has an "equal weight" rating on the medical research company's stock. Barclays's price objective would indicate a potential upside of 12.19% from the stock's current price.

A number of other equities research analysts have also recently issued reports on the stock. Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Argus decreased their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Evercore ISI cut their price target on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Scotiabank dropped their target price on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research report on Friday, April 25th. Finally, Stifel Nicolaus decreased their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $604.05.

Thermo Fisher Scientific Stock Up 0.2%

Shares of TMO traded up $0.89 during trading hours on Tuesday, hitting $401.10. 619,925 shares of the company were exchanged, compared to its average volume of 1,939,856. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The company has a market cap of $151.41 billion, a PE ratio of 23.53, a PEG ratio of 2.10 and a beta of 0.78. The firm's 50 day moving average is $411.66 and its 200-day moving average is $486.42. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The company's quarterly revenue was up .2% compared to the same quarter last year. During the same quarter last year, the firm posted $5.11 earnings per share. On average, equities research analysts forecast that Thermo Fisher Scientific will post 23.28 EPS for the current fiscal year.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.33% of the stock is owned by corporate insiders.

Institutional Trading of Thermo Fisher Scientific

Large investors have recently made changes to their positions in the business. Bernard Wealth Management Corp. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $25,000. CBIZ Investment Advisory Services LLC raised its position in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after acquiring an additional 33 shares during the last quarter. Pillar Financial Advisors LLC acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at $29,000. Ameriflex Group Inc. acquired a new stake in Thermo Fisher Scientific in the fourth quarter worth about $30,000. Finally, Anderson Financial Strategies LLC bought a new stake in Thermo Fisher Scientific during the 1st quarter worth about $30,000. Institutional investors own 89.23% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.